Sectors
Life Sciences & Healthcare

Life Sciences & Healthcare

Get in touch

We are the legal advisors of choice to many prestigious clients in the Life Sciences and Healthcare industry. In an industry that is driven by innovation and discovery, we pride ourselves on providing dynamic and pragmatic advice to our clients. Our specialists, with a wide range of scientific backgrounds, have deep sector knowledge and extensive experience working across the spectrum of disciplines within the Life Sciences & Healthcare industry.

Cannabis

Agrochemicals

Cell and gene therapy

Healthcare

Europe offers a world-class science base with a thriving ecosystem, which boasts a rich array of entities ranging from start-ups all the way up to some of the world's largest pharmaceutical companies.

During an unprecedented time of innovation, it is vital to have in place professional advisors that have the necessary capabilities to adapt just as rapidly and can provide the right support and input exactly when and where it is needed.

Why choose our Life Sciences & Healthcare Lawyers?

Fieldfisher's cross-departmental collaboration across of all our offices means that we provide seamlessly sector-relevant multifaceted legal support. With a wealth of experience advising small and large entities alike, our expertise across key subsectors, including digital health, agrochemicals, cannabis and cell and gene therapy, means we deliver meaningful and impactful value to our clients.

Our ongoing work and active participation in leading industry bodies, such as ABHI, BIA and EUCOP and support of their respective member companies, means that we are more than just a legal services provider and are an imbedded part of the industry's ecosystem.

Fieldfisher is internationally recognised for its work in the regulatory environment and routinely advises on the implications of current and future regulation in the life sciences and healthcare industry. By being at the forefront of regulation, we provide thought leadership on technology solutions, which includes AI and how it is deployed across the industry. Continued technological and scientific advancement brings with it significant changes in both the regulatory and legislative landscape and forthcoming changes will require ongoing internal review and consultation in order to avoid complications and setbacks.

Notable Deals

Advising Roche Products Limited on its contributions unlicensed medicines

Advising Roche Products Limited on its contributions unlicensed medicines for treatment for and help with management of the Covid-19 virus, including various aspects of the clinical trials processes. In addition to this, Our Life Sciences team have also continued to support oncology and ophthalmology medications, labelling Brexit and export control issues as the medical giant navigate new challenges. Our team also advised Roche Products on two research collaboration agreements.

Advised Ultromics, a leader in AI enabled cardiovascular imaging solutions

Advised Ultromics, a leader in AI enabled cardiovascular imaging solutions, on its Series B funding round led by the Blue Venture Fund with participation from Optum Ventures, GV, and existing investor Oxford Sciences Innovation, to help transform cardiac disease treatment. Fieldfisher advised UK headquartered MedTech company Ultromics, a leader in AI enabled cardiovascular imaging solutions, on its Series B funding round led by the Blue Venture Fund with participation from Optum Ventures, GV, and existing investor Oxford Sciences Innovation, to help transform cardiac disease treatment. We further advised Ultromics on complex contracts in relation to them winning a competition for a phase 3 and phase 4 grant sponsored by the NHS and related bodies to implement AI technology into the NHS

Advised Synairgen in relation to a Phase III Clinical Trial

Advised Synairgen in relation to a Phase III Clinical Trial for their interferon Beta therapeutic inhaled treatment for Covid-19. We advised Synairgen in relation to a Phase III Clinical Trial for their interferon Beta therapeutic inhaled treatment for covid-19, which completed on 10 February 2022. In addition to this, we also advised Synairgen on a major fundraising primarily intended to enable them to progress with the Phase III clinical trials, enrolling participants across multiple countries, and fund manufacturing and device scale-up activities. The transaction was one of largest public fundraisings in the biotech sector for several years and followed a £14 million fundraising Fieldfisher advised the company on in March 2020.

Key contacts

Olivier Lantrès

Partner, Co-head of Life Sciences & Healthcare
Paris, France +33 (0)1 70 37 81 00 Email Olivier

Life Sciences and Healthcare
Dr Cord Willhöft, LL.M. (KCL)

Partner, Co-Head of Life Sciences & Healthcare
Munich, Germany +49 (0)89 620 306 245 Email Dr Cord

Commercial

Life Sciences & Healthcare
Sarah Ellson

Partner, Co-Head of Regulatory
Manchester, England +44 330 460 7019 Email Sarah

Healthcare

Investigations

Life Sciences & Healthcare

Professional Discipline
Robert Jappie

Partner
London, England Email Robert

Food and Beverage

Healthcare

Life Sciences & Healthcare

Public and Regulatory
Héctor Jausàs

Partner
Barcelona, Spain +34 934 150 088 Email Héctor

Life Sciences & Healthcare
Sarah Tedstone

Partner
London, England +44 330 460 6303 Email Sarah

Artificial Intelligence

Data Protection and Privacy

Life Sciences & Healthcare

Technology and Data
Janita Good

Partner
London, England +44 330 460 6397 Email Janita

Corporate